AI-Designed Drugs by a DeepMind Spinoff Are Headed to Human Trials

Isomorphic Labs president Max Jaderberg said at WIRED Health in London that the startup has built a "broad and exciting pipeline of new medicines." Google DeepMind's AlphaFold has already revolutionized scientists' understanding of proteins . Now, the ability of the platform to design safe and effective drugs is about to be put to the test. Isomorphic Labs, the UK-based biotech spinoff of Google DeepMind, will soon begin human trials of drugs designed by its Nobel Prize-winning AI technology. "We're gearing up to go into the clinic," Isomorphic Labs president Max Jaderberg said on April 16 at WIRED Health in London.